140 related articles for article (PubMed ID: 30985573)
1. Donor Age Predicts Calcineurin Inhibitor Induced Neurotoxicity After Liver Transplantation.
Lué A; Martinez E; Navarro M; Laredo V; Lorente S; Jose Araiz J; Agustin Garcia-Gil F; Serrano MT
Transplantation; 2019 Aug; 103(8):e211-e215. PubMed ID: 30985573
[TBL] [Abstract][Full Text] [Related]
2. Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation.
Balderramo D; Prieto J; Cárdenas A; Navasa M
Transpl Int; 2011 Aug; 24(8):812-9. PubMed ID: 21649743
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive risk assessment for early neurologic complications after liver transplantation.
Wu SY; Chen TW; Feng AC; Fan HL; Hsieh CB; Chung KP
World J Gastroenterol; 2016 Jun; 22(24):5548-57. PubMed ID: 27350733
[TBL] [Abstract][Full Text] [Related]
4. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
[TBL] [Abstract][Full Text] [Related]
5. Incidence, Predictors, and Impact on Survival of Long-term Cardiovascular Events After Liver Transplantation.
Sastre L; García R; Gándara JG; Ruiz P; Lombardo J; Colmenero J; Navasa M; Crespo G
Transplantation; 2020 Feb; 104(2):317-325. PubMed ID: 31335770
[TBL] [Abstract][Full Text] [Related]
6. Conversion From Once-Daily Prolonged-Release Tacrolimus to Once-Daily Extended-Release Tacrolimus in Stable Liver Transplant Recipients.
Altieri M; Delaval G; Kimmoun E; Allaire M; Salamé E; Dumortier J
Exp Clin Transplant; 2018 Jun; 16(3):321-325. PubMed ID: 28697715
[TBL] [Abstract][Full Text] [Related]
7. Differences in the incidence and clinical evolution of early neurotoxicity after liver transplantation based on tacrolimus formulation used in the immunosuppressive induction protocol.
Souto-Rodríguez R; Molina-Pérez E; Castroagudín JF; Fernández Pérez A; Otero-Antón E; Tomé Martínez de Rituerto S; Martínez-Castro J; Varo-Pérez E
Transplant Proc; 2014 Nov; 46(9):3117-20. PubMed ID: 25420839
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.
Hao JC; Wang WT; Yan LN; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
World J Gastroenterol; 2014 Aug; 20(32):11356-62. PubMed ID: 25170222
[TBL] [Abstract][Full Text] [Related]
9. Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An Extension Study.
Adam R; Karam V; Cailliez V; Trunečka P; Samuel D; Tisone G; Němec P; Soubrane O; Schneeberger S; Gridelli B; Bechstein WO; Risaliti A; Line PD; Vivarelli M; Rossi M; Pirenne J; Klempnauer JL; Rummo A; Di Benedetto F; Zieniewicz K; Troisi R; Paul A; Vali T; Kollmar O; Boudjema K; Hoti E; Colledan M; Pratschke J; Lang H; Popescu I; Ericzon BG; Strupas K; De Simone P; Kochs E; Heyd B; Gugenheim J; Pinna AD; Bennet W; Kazimi M; Bachellier P; Wigmore SJ; Rasmussen A; Clavien PA; Hidalgo E; O'Grady JG; Zamboni F; Kilic M; Duvoux C;
Transplantation; 2019 Sep; 103(9):1844-1862. PubMed ID: 31343568
[TBL] [Abstract][Full Text] [Related]
10. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
[TBL] [Abstract][Full Text] [Related]
11. Liver transplantation and neurological side effects.
Saner FH; Nadalin S; Radtke A; Sotiropoulos GC; Kaiser GM; Paul A
Metab Brain Dis; 2009 Mar; 24(1):183-7. PubMed ID: 19139982
[TBL] [Abstract][Full Text] [Related]
12. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
Berenguer M; Aguilera V; San Juan F; Benlloch S; Rubin A; López-Andujar R; Moya A; Pareja E; Montalva E; Yago M; de Juan M; Mir J; Prieto M
Transplantation; 2010 Dec; 90(11):1204-9. PubMed ID: 21068701
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus-Induced Neurotoxicity in Early Post-Liver Transplant Saudi Patients: Incidence and Risk Factors.
Alissa DA; Alkortas D; Alsebayel M; Almasuood RA; Aburas W; Altamimi T; Devol EB; Al-Jedai AH
Ann Transplant; 2022 May; 27():e935938. PubMed ID: 35578566
[TBL] [Abstract][Full Text] [Related]
14. Early predictors of renal dysfunction in cirrhotic patients after liver transplantation.
Piñero F; Bandi J; Tisi Baña M; Casciato P; Villamil A; Galdame O; de Santibañés E; Gadano A
Acta Gastroenterol Latinoam; 2014; 44(4):316-22. PubMed ID: 26753383
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation.
Vandevoorde K; Ducreux S; Bosch A; Guillaud O; Hervieu V; Chambon-Augoyard C; Poinsot D; André P; Scoazec JY; Robinson P; Boillot O; Dubois V; Dumortier J
Liver Transpl; 2018 Aug; 24(8):1091-1100. PubMed ID: 29665189
[TBL] [Abstract][Full Text] [Related]
16. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study.
Trunečka P; Klempnauer J; Bechstein WO; Pirenne J; Bennet W; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Kazeem G; Tisone G
Ann Transplant; 2019 Jun; 24():319-327. PubMed ID: 31160549
[TBL] [Abstract][Full Text] [Related]
18. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience.
Ayar Y; Ersoy A; Ocakoglu G; Yildiz A; Oruc A; Soyak H; Calapkulu M; Sahin AB; Topal NB; Okeer E; Coskun B; Kaygisiz O; Kordan Y; Vuruskan H
Transplant Proc; 2017 Mar; 49(2):270-277. PubMed ID: 28219583
[TBL] [Abstract][Full Text] [Related]
20. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
